Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines.

ABSTRACT:

Background

Chemotherapy remains the first-line treatment for triple-negative breast cancer (TNBC). Anthracycline chemotherapeutics, such as epirubicin (EPI), not only kill tumor cells but also induce immunogenic cell death (ICD). However, accumulated extracellular adenosine triphosphate (eATP) during ICD is converted to adenosine, triggering immunosuppression via adenosine receptor signalling. To address this issue, co-administration of EPI with adenosine receptor antagonists could remodel the immunosuppressive tumor microenvironment and potentiate antitumor immunity.

Methods

The effect of the expression level of adenosine receptors on the immune microenvironment of TNBC was assessed by integrating bioinformatic analysis of public databases with immunofluorescence staining o

SUBMITTER: Cheng X 

PROVIDER: S-EPMC12721312 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature